Clinical trials: Acute Intermittent Porphyria (AIP)
Porphyrias
Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria
This is an observational study collecting patient/caregiver reports on suspected medication/drug-induced acute porphyria attacks, as well as safe use of drugs previously labeled "unsafe" or with unknown risk.
- Trial name
- NCT03906214
- Testing
- Web-based Survey
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of South Florida
Acute Intermittent Porphyria
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
This is a Phase I trial aimed to determine the safety of the investigational gene therapy product (rAAV2/5-PBGD) for the treatment of Acute Intermittent Porphyria (AIP).
- Trial name
- NCT02082860
- Testing
- rAAV2/5-PBGD vector dosage 1, rAAV2/5-PBGD vector dosage 2, rAAV2/5-PBGD vector dosage 3
- Where
- 2 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Digna Biotech S.L.